Abbott Atrial Fibrillation Post Approval Study

Atrial Arrhythmia Clinical Trial

Official title:

Abbott Atrial Fibrillation Post Approval Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05434650
• Other study ID #: ABT-CIP-10436
• Status: Recruiting
• Start date: October 21, 2022
• Est. completion date: November 30, 2026

Study information

• Verified date: May 2024
• Source: Abbott Medical Devices
• Contact: Todd Stirman
• Phone: 972-526-9625
• Email: todd.stirman[@]abbott.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This post-approval study is designed to provide continued real-world clinical evidence to confirm the safety and long-term effectiveness of atrial fibrillation (AF) radiofrequency (RF) technologies (e.g. TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)) for the treatment of AF.

Description:

This post-approval study is a prospective, non-randomized, single arm, multicenter, observational study to evaluate the continued safety and effectiveness of AF RF technologies, including the TactiCath SE. The primary effectiveness endpoint will be the proportion of subjects with freedom from AF recurrence after the initial catheter ablation procedure through 12 months of follow-up (includes a 90-day blanking period). Secondary effectiveness endpoints will be the proportion of subjects with freedom from AF recurrence after the initial catheter ablation procedure through 24 and 36 months of follow-up (includes a 90-day blanking period). The acute primary safety endpoint will be the rate of device and/or procedure-related serious adverse events (SAE) with onset within 7-days of the index ablation procedure utilizing the study catheter. The secondary, long-term safety endpoint will be the rate of device and/or procedure-related SAEs from the index ablation procedure. An independent Clinical Event Committee (CEC) will review all Adverse Device Effects (ADEs) and SAEs and will adjudicate causality relative to the primary safety endpoints.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: November 30, 2026
• Est. primary completion date: October 31, 2024
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Subject must provide written informed consent prior to any clinical investigation-related procedure.

2. Documented symptomatic persistent AF, which is defined as continuous AF sustained beyond 7 days and less than 1 year that is documented by a physician's note AND one of the following:

1. a 24-hour Holter within 180 days prior to consent/enrollment, showing continuous AF OR

2. two electrocardiograms (from any form of rhythm monitoring) showing continuous AF:

i. that are taken at least 7 days apart but less than 12 months apart. ii. If electrocardiograms are more than 12 months apart, there must be one or more SR recordings in between or within 12 months prior to consent/enrollment NOTE: The most recent ECG must be within 180 days of consent/enrollment. Documented evidence of the AF episode must either be continuous AF on a 12-lead ECG or include at least 30 seconds of AF from another ECG device.

3. Subject must have failed, intolerance, or contraindication to a Class I-IV AAD medication.

4. Able and willing to comply with all pre-, post-, and follow-up testing and requirements

Exclusion Criteria:

1. Previously diagnosed continuous AF >12 months (longstanding persistent AF)

2. Previous left atrial surgical or catheter ablation for atrial fibrillation or a previous procedure that required an incision in the left atrium with resulting scar

3. Documented or known intracardiac thrombus on imaging

4. History of atriotomy or ventriculotomy within 4 weeks prior to the initial procedure

5. Patients with prosthetic valves

6. Diagnosed atrial myxoma

7. Acute illness or active systemic infection or sepsis

8. Patient is unlikely to survive the protocol follow up period of 36 months

9. Presence of other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results

10. Enrollment in an investigational study evaluating another device, biologic, or drug that may interfere with this clinical investigation at the time of the initial procedure or within 30 days prior to the initial procedure

11. Investigator deems at the time of screening for inclusion in the study that the patient's treatment plan does not or likely will not include use of the study catheter

Related Conditions & MeSH terms

• Atrial Arrhythmia
• Atrial Fibrillation
• Atrial Tachycardia
• Atrium; Fibrillation
• Tachycardia

Intervention

Device:
• electrophysiology study and ablation with an Abbott Ablation Catheter
During the cardiac ablation procedure, an ablation catheter (a thin, flexible tube that can be threaded through the blood vessels to the heart) will deliver radiofrequency energy (a type of heat) to one or more areas in the upper left chamber of the heart that is causing the irregular heartbeat. The tip of the catheter will transmit energy to one or more small spots of heart tissue. This energy creates a small scar on the heart. This scar will block the electrical pathway that is causing the rapid heartbeat

Locations

Country	Name	City	State
United States	Northside Hospital	Atlanta	Georgia
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Brigham & Women's Hospital	Boston	Massachusetts
United States	Erlanger Medical Center	Chattanooga	Tennessee
United States	Doylestown Hospital	Doylestown	Pennsylvania
United States	Heart Center Research, LLC.	Huntsville	Alabama
United States	Arkansas Cardiology	Little Rock	Arkansas
United States	St. Patrick Hospital	Missoula	Montana
United States	Centennial Medical Center	Nashville	Tennessee
United States	Ochsner Medical Center	New Orleans	Louisiana
United States	Sentara Norfolk General Hospital	Norfolk	Virginia
United States	Oklahoma Heart Hospital South	Oklahoma City	Oklahoma
United States	University of Nebraska Medical Center	Omaha	Nebraska
United States	Eisenhower Medical Center	Rancho Mirage	California
United States	Sequoia Hospital	Redwood City	California
United States	Chippenham Hospital	Richmond	Virginia
United States	St. Marks Hospital	Salt Lake City	Utah
United States	Methodist Hospital of San Antonio	San Antonio	Texas
United States	Providence Hospital	Southfield	Michigan
United States	North Mississippi Medical Center	Tupelo	Mississippi

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Medical Devices

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of subjects with freedom from AF recurrence post 90-day blanking period at 12 months	AF recurrence is defined as: Documented AF/atrial flutter (AFL)/atrial tachycardia (AT) episodes of > 30 seconds duration following the blanking period; Repeat ablation for AF/AFL/AT following the blanking period; Cardioversion (electrical or pharmaceutical) for the treatment of AF following the blanking period; A new Class I/III AAD or a previously failed Class I/III AAD at a dose greater than the highest historical dose for AF is needed following the blanking period	12 months
Primary	Rate of device and/or procedure-related serious adverse events (SAE) with onset within 7-days of the index ablation procedure	Device and/or index procedure-related SAEs are defined below: Atrio-esophageal fistula; Cardiac tamponade/perforation; Death; Heart block; Myocardial infarction (MI); Pericarditis; Phrenic nerve injury resulting in diaphragmatic paralysis; Vagal nerve injury/gastroparesis; Pulmonary edema (respiratory insufficiency); Pulmonary vein stenosis; Stroke/cerebrovascular accident (CVA); Thromboembolism; Transient ischemic attack; Vascular access complications (including major bleeding events3)	7 days
Secondary	the proportion of subjects with freedom from AF recurrence post 90-day blanking period at 24 months and 36 months	AF recurrence is defined as: Documented AF/atrial flutter (AFL)/atrial tachycardia (AT) episodes of > 30 seconds duration following the blanking period; Repeat ablation for AF/AFL/AT following the blanking period; Cardioversion (electrical or pharmaceutical) for the treatment of AF following the blanking period; A new Class I/III AAD or a previously failed Class I/III AAD at a dose greater than the highest historical dose for AF is needed following the blanking period	36 months
Secondary	the rate of device and/or procedure-related SAEs from the index ablation procedure, descriptively evaluated at 12 months, 24 months, and 36 months	Device and/or index procedure-related SAEs are defined below: Atrioesophageal fistula; Cardiac tamponade/perforation; Death; Heart block; Myocardial infarction (MI); Pericarditis; Phrenic nerve injury resulting in diaphragmatic paralysis; Pneumothorax; Pulmonary edema (respiratory insufficiency); Pulmonary vein stenosis; Stroke/cerebrovascular accident (CVA); Thromboembolism; Transient ischemic attack; Vascular access complications (including major bleeding events)	36 months